EC-NGF biodelivery devices targeting the basal forebrain of implanted AD patients (n = 6) are safe in a 12-month study, leading to improvement in cognition assessed by clinical rating scales, EEG, MRI, and positron emission tomography (PET) (Eriksdotter-Jönhagen et al., 2012). Here, NGF is linked to Alzheimer disease.